Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Clinical trial NCT07106762 · RECRUITING
Trial details
- NCT number
- NCT07106762
- Sponsor
- Bristol-Myers Squibb
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-30
- Primary completion
- 2029-01-26
- Enrollment
- 470
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.